CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 128 enrolled
Drug / intervention
Arginine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00513617
NCT00513617Phase 2Completed
CompareCT.gov

Arginine Supplementation in Sickle Cell Anemia: Physiological and Prophylactic Effects

UCSF Benioff Children's Hospital Oakland·interventional·Posted Aug 8, 2007·Updated Mar 29, 2017

In Brief

A Phase 2 clinical trial evaluating Arginine and Placebo for Anemia, Sickle Cell. Completed, enrolled 128 participants across 17 sites.

Detailed Summary

Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited genetic disease that can cause intense pain episodes. This study will evaluate the effectiveness of the nutritional supplement arginine at improving blood cell function and disease symptoms in people with SCD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Sickle Cell
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 8, 2007
Enrollment StartJun 1, 2004
Primary CompletionSep 1, 2007
Study CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 18.9 years ago

Interventions

Argininedrug

Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.

Placebodrug

Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.